Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.46 |
| ▸ | CSF1R | P07333 | 4/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366285 | 0.95 | KDR (0.45) | METKDRPDGFRACSF1RPDGFRB | |
| SCHEMBL13861127 | 0.87 | HRH3 (0.45) | METKDRMAPK14GCKHRH3 | |
| SCHEMBL4333839 | 0.83 | HRH3 (0.45) | METKDRMAPK14GCKHRH3 | |
| SCHEMBL14366284 | 0.83 | MET (0.48) | METKDRPDGFRACSF1RPDGFRB | |
| SCHEMBL4330552 | 0.82 | MEN1 (0.43) | METKDRPDGFRAGCKKIT | |
| SCHEMBL14366283 | 0.81 | KDR (0.47) | METKDRPDGFRACSF1RPDGFRB | |
| SCHEMBL3558791 | 0.80 | MET (0.49) | METKDRPDGFRBFLT3MAPK14 | |
| SCHEMBL14366276 | 0.79 | MET (0.63) | METKDRPDGFRACSF1RPDGFRB | |
| SCHEMBL4326095 | 0.79 | CYP1A2 (0.44) | KDRPDGFRBMAPK14GCKKIT | |
| SCHEMBL1137061 | 0.79 | MET (0.66) | METKDRPDGFRACSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | MET 2/4885KDR 7/4885PDGFRA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.